

Sir,

Please find below the corrections you have asked for the manuscript:

Name of the journal: World Journal of Pharmacology

Manuscript NO: 22765

Column: Minireviews

Title: Adalimumab and pharmacokinetics: impact on the clinical prescription for inflammatory bowel disease

The Running title has been added: Adalimumab and pharmacokinetics for clinical practice.

Conflict of interest statement is completed and we provided a file with signatures.

Anne-Laure Pelletier has not received fees for serving as a speaker or as consultant or advisory board member of any organization. Anne-Laure Pelletier has not received research funding. Anne-Laure Pelletier is not an employee of another organization. She does not own stocks and/or shares of organization nor patent.

Pascale Nicaise-Roland has not received fees for serving as a speaker or as consultant or advisory board member of any organization. Pascale Nicaise-Roland has not received research funding. Pascale Nicaise-Roland is not an employee of another organization. She does not own stocks and/or shares of organization nor patent.

The authors address have been completed

An explanation for inter patient variability is given in the article: One hypothesis is that the overall inflammatory burden in patients with ulcerative colitis is higher with a greater area of mucosal lesions and a greater loss of medication in the intestinal lumen. It is highlighted in red.

A table has been added that shows the factors influencing Adalimumab response.

Corrections have been made in the "Adalimumab and anti-adalimumab antibody detection" section. They are highlighted in red.

An audio core tip is send.

The paper was corrected and edited by a professional translator and editor with more than 25 years' experience who is a native English speaker.

The final title has been searched on Google Scholar and I join the screenshot results below. The organization for which I am working is not a PILA member and I have no access to crossref.

We followed the references guidelines.

Home - PubMed - NCBI | Portail Orange : Actu, Spor... | Adalimumab and pharmac... | Word - Insérer des capture... | dosage erbitux - Recherche... | +

https://scholar.google.fr/scholar?hl=fr&q=Adalimumab+and+pharmacokinetics%3A+impact+on+the+clinical | dosage erbitux

Les plus visités | Web | Images | Plus... | Connexion

Google | Adalimumab and pharmacokinetics: impact on the clinical prescription for in |

Scholar | Environ 3 230 résultats (0,10 s) | Mes citations

Articles

Conseil : Recherchez des résultats uniquement en Français. Vous pouvez indiquer votre langue de recherche sur la page Paramètres Google Scholar.

Ma bibliothèque

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial [PDF] à partir de ucsd.edu
 JF Colombel, WJ Sandborn, P Rutgeerts, R Enns... - Gastroenterology, 2007 - Elsevier
 ... Adalimumab (Humira, Abbott Laboratories, Abbott Park, IL) is a subcutaneously administered, recombinant, fully human, immunoglobulin G1 ... 40-mg every other week groups (33%) and lower in the adalimumab 40-mg weekly ... Baseline Demographics and Clinical Characteristics. ...
 Cité 1334 fois | Autres articles | Les 13 versions | Web of Science: 783 | Citer | Enregistrer

Date indifférente

Depuis 2015

Depuis 2014

Depuis 2011

Période spécifique...

Trier par pertinence

Trier par date

Rechercher sur le Web

Rechercher les pages en Français

inclure les brevets

inclure les citations

Créer l'alerte

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I Trial [PDF] à partir de ucsd.edu
 SB Hanauer, WJ Sandborn, P Rutgeerts, RN Fedorak... - Gastroenterology, 2006 - Elsevier
 ... Adalimumab (D2E7, Humira, Abbott Laboratories, Chicago, IL) is a recombinant human immunoglobulin G1 (IgG ... Based on results from pharmacokinetic modeling of data from patients with rheumatoid arthritis ... mg (n = 74), Adalimumab 80 mg/40 mg (n = 75), Adalimumab 160 mg ...
 Cité 1096 fois | Autres articles | Les 12 versions | Web of Science: 645 | Citer | Enregistrer

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease [HTML] à partir de nature.com
 WJ Sandborn, S Hanauer, EV Loftus... - The American journal of ..., 2004 - nature.com
 ... are relatively less immunogenic than chimeric monoclonal antibodies (9). Adalimumab (Humira® , Abbott Laboratories ... Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal ... Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti ...
 Cité 310 fois | Autres articles | Les 7 versions | Web of Science: 167 | Citer | Enregistrer

Infliximab, azathioprine, or combination therapy for Crohn's disease [PDF] à partir de fundapoyarte.org
 JF Colombel, WJ Sandborn, W Reinisch... - ... England Journal of ..., 2010 - Mass Medical Soc
 ... been due in part to suppression of immunogenicity, it is likely that the enhanced benefit was primarily due to the additive effects of two ... Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. ... 2014) Adalimumab drug and ...
 Cité 1346 fois | Autres articles | Les 40 versions | Citer | Enregistrer

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial [PDF] à partir de researchgate.net
 G Van Assche, C Magdeleine-Beuzelin, G D'Haens... - Gastroenterology, 2008 - Elsevier
 ... The influence of withdrawing immunosuppressives on the pharmacokinetics of infliximab had no major impact on the ... If this were true, it may negatively impact on patient outcomes because a recent controlled trial with another anti-TNF antibody, adalimumab, indicated that ...
 Cité 353 fois | Autres articles | Les 16 versions | Web of Science: 217 | Citer | Enregistrer

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial [HTML] à partir de bmj.com

11:48 05/11/2015